NovAliX is a drug discovery-focused CRO, highly proficient in chemistry and biophysics, with several unique technologies. The company has set up one of the world’s most comprehensive biophysics platforms, from screening to identification and detailed characterization of drug-target interactions using protein X-ray crystallography, native MS, NMR, SPR, and cryo-EM. Our award-winning chemistry teams have delivered on numerous projects in medicinal chemistry, process research, and discovery chemistry. NovAliX’ innovative, cost-effective, collaborative, and co-located research programs involve dedicated teams of scientists working throughout Europe in its partners’ laboratories. Close proximity fosters the seamless transfer of knowledge in both directions and speeds up the research process. NovAliX, founded in 2002, is based in Strasbourg, France, in the heart of the BioValley Upper Rhine region, France.